NO20073283L - Nye pyridotienopyrimidinderivater - Google Patents
Nye pyridotienopyrimidinderivaterInfo
- Publication number
- NO20073283L NO20073283L NO20073283A NO20073283A NO20073283L NO 20073283 L NO20073283 L NO 20073283L NO 20073283 A NO20073283 A NO 20073283A NO 20073283 A NO20073283 A NO 20073283A NO 20073283 L NO20073283 L NO 20073283L
- Authority
- NO
- Norway
- Prior art keywords
- group
- alkyl groups
- alkyl
- groups
- independently selected
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- -1 monoalkylamino Chemical group 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Anvendelse av et pyridotienopyrimidinderivat med formel (I) og de farmasøytisk akseptable salter og N-oksider derav, hvori G1 representerer en gruppe valgt fra -CR6R7- eller -NR6 med R6 og R7 uavhengig valgt fra hydrogenatomer og C1-4alkylgrupper, m og n er hele tall valgt fra 0 eller 1, R1 og R2 er uavhengig valgt fra hydrogenatomer og C1-4alkylgrupper, R3 representerer en gruppe valgt fra alkyl, amino, monoalkylamino, dialkylamino, aryl, heteroaryl og mettede N-inneholdende heterocyklylgrupper bundet via nitrogenatomet til pyridinringen, og alle er de valgfritt substituert med en eller flere substituenter valgt fra gruppen bestående av halogenatomer og alkyl, alkoksyalkyl, arylalkyl, R8OCO-, alkoksy, R8R9N-CO-, -CN, -CF3, -NR8R9, -SR8 og -SO2NH2, hvori R8 og R9 er uavhengig valgt fra hydrogenatomer og C1-4alkylgrupper, R4 og R5 er uavhengig valgt fra gruppen bestående av hydrogenholdige alkylgrupper og grupper med formel (II): (II) hvori p og q er hele tall valgt fra 1, 2 og 3; A er enten en direkte binding eller en gruppe valgt fra -CONR14-, -NR14CO-, -O-, -COO-, -OCO-, -NR14COO-, -OCONR14-, -NR14CONR15-, -S-, -SO-, -SO2-, -COS- og -SCO-; og G2 er en gruppe valgt fra aryl, heteroaryl eller heterocyklyl; hvori alkylgruppene, og gruppen G2 er valgfritt substituert med en eller flere substituenter valgt fra gruppen bestående av halogenatomer og alkyl, alkoksyalkyl, arylalkyl, R16OCO-, hydroksy, alkoksy, okso, R16R17NCO-, -CN, -CF3, -NR16R17, -SR16 og -SO2NH2-grupper; hvori R10 til R17 er uavhengig valgt fra hydrogenatomer og C1-4alkylgrupper; i fremstillingen av et medikament for behandling eller forhindring av en patologisk tilstand eller sykdom som er mottagelig for bedring ved inhibisjon av fosfodiesterase 4. ?? ?? ?? ??
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200402876A ES2259891B1 (es) | 2004-11-30 | 2004-11-30 | Nuevos derivados de piridotienopirimidina. |
| PCT/EP2005/012774 WO2006058724A1 (en) | 2004-11-30 | 2005-11-30 | New pyridothienopyrimidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20073283L true NO20073283L (no) | 2007-06-27 |
Family
ID=35064879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20073283A NO20073283L (no) | 2004-11-30 | 2007-06-27 | Nye pyridotienopyrimidinderivater |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20090029955A1 (no) |
| EP (1) | EP1819710B1 (no) |
| JP (1) | JP2008521855A (no) |
| KR (1) | KR20070086869A (no) |
| CN (1) | CN101068816A (no) |
| AR (1) | AR051686A1 (no) |
| AT (1) | ATE425167T1 (no) |
| AU (1) | AU2005311423A1 (no) |
| BR (1) | BRPI0518094A (no) |
| CA (1) | CA2588741A1 (no) |
| DE (1) | DE602005013278D1 (no) |
| ES (2) | ES2259891B1 (no) |
| HK (1) | HK1101638A1 (no) |
| IL (1) | IL183142A0 (no) |
| MX (1) | MX2007006173A (no) |
| NO (1) | NO20073283L (no) |
| PE (1) | PE20061078A1 (no) |
| RU (1) | RU2007124326A (no) |
| TW (1) | TW200635932A (no) |
| UY (1) | UY29239A1 (no) |
| WO (1) | WO2006058724A1 (no) |
| ZA (1) | ZA200703827B (no) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| ES2281251B1 (es) * | 2005-07-27 | 2008-08-16 | Laboratorios Almirall S.A. | Nuevos derivados de pirido (3',2':4,5) furo (3,2-d) pirimidina. |
| JP2009508966A (ja) * | 2005-09-23 | 2009-03-05 | シェーリング コーポレイション | 治療薬としての縮合四環性ｍＧｌｕＲ１アンタゴニスト |
| WO2011128263A1 (de) * | 2010-04-14 | 2011-10-20 | Bayer Cropscience Ag | Verfahren zur herstellung von dithiin-tetracarboximiden |
| EP4186910A1 (en) | 2016-06-22 | 2023-05-31 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| CN109862893B (zh) | 2016-11-07 | 2023-02-17 | 范德比尔特大学 | 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂 |
| BR112018013879A2 (pt) | 2016-11-07 | 2018-12-11 | Univ Vanderbilt | moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4 |
| MA46722A (fr) | 2016-11-07 | 2019-09-11 | Univ Vanderbilt | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 |
| TW201930311A (zh) | 2017-12-05 | 2019-08-01 | 泛德比爾特大學 | 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑 |
| US11376254B2 (en) | 2017-12-05 | 2022-07-05 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| US20230084927A1 (en) * | 2019-11-13 | 2023-03-16 | Metabomed Ltd. | Glucose uptake inhibitors and uses thereof |
| CN115684415B (zh) * | 2022-11-02 | 2024-09-10 | 山东华泰新材料技术研发有限公司 | 一种高效液相色谱测定5,6-二氢环戊并[b]噻吩-4-酮含量的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19644228A1 (de) * | 1996-10-24 | 1998-04-30 | Merck Patent Gmbh | Thienopyrimidine |
| DE19752952A1 (de) * | 1997-11-28 | 1999-06-02 | Merck Patent Gmbh | Thienopyrimidine |
| DE19819023A1 (de) * | 1998-04-29 | 1999-11-04 | Merck Patent Gmbh | Thienopyrimidine |
| EP1323719A1 (en) * | 1999-03-30 | 2003-07-02 | Nippon Soda Co., Ltd. | Thienopyrimidine compounds and salts thereof and process for the preparation of the same |
-
2004
- 2004-11-30 ES ES200402876A patent/ES2259891B1/es not_active Expired - Fee Related
-
2005
- 2005-11-28 PE PE2005001379A patent/PE20061078A1/es not_active Application Discontinuation
- 2005-11-28 AR ARP050104956A patent/AR051686A1/es unknown
- 2005-11-29 UY UY29239A patent/UY29239A1/es unknown
- 2005-11-30 RU RU2007124326/04A patent/RU2007124326A/ru not_active Application Discontinuation
- 2005-11-30 AU AU2005311423A patent/AU2005311423A1/en not_active Abandoned
- 2005-11-30 DE DE602005013278T patent/DE602005013278D1/de not_active Expired - Fee Related
- 2005-11-30 WO PCT/EP2005/012774 patent/WO2006058724A1/en active Application Filing
- 2005-11-30 TW TW094142175A patent/TW200635932A/zh unknown
- 2005-11-30 EP EP05814833A patent/EP1819710B1/en active Active
- 2005-11-30 AT AT05814833T patent/ATE425167T1/de not_active IP Right Cessation
- 2005-11-30 BR BRPI0518094-5A patent/BRPI0518094A/pt not_active IP Right Cessation
- 2005-11-30 MX MX2007006173A patent/MX2007006173A/es not_active Application Discontinuation
- 2005-11-30 CN CNA200580040992XA patent/CN101068816A/zh active Pending
- 2005-11-30 US US11/791,450 patent/US20090029955A1/en not_active Abandoned
- 2005-11-30 ES ES05814833T patent/ES2321966T3/es active Active
- 2005-11-30 JP JP2007543767A patent/JP2008521855A/ja active Pending
- 2005-11-30 CA CA002588741A patent/CA2588741A1/en not_active Abandoned
- 2005-11-30 KR KR1020077015102A patent/KR20070086869A/ko not_active Application Discontinuation
-
2007
- 2007-05-10 IL IL183142A patent/IL183142A0/en unknown
- 2007-05-11 ZA ZA200703827A patent/ZA200703827B/xx unknown
- 2007-06-27 NO NO20073283A patent/NO20073283L/no not_active Application Discontinuation
- 2007-08-28 HK HK07109343.8A patent/HK1101638A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070086869A (ko) | 2007-08-27 |
| RU2007124326A (ru) | 2009-01-10 |
| WO2006058724A1 (en) | 2006-06-08 |
| ES2321966T3 (es) | 2009-06-15 |
| ES2259891B1 (es) | 2007-11-01 |
| CA2588741A1 (en) | 2006-06-08 |
| AR051686A1 (es) | 2007-01-31 |
| TW200635932A (en) | 2006-10-16 |
| JP2008521855A (ja) | 2008-06-26 |
| BRPI0518094A (pt) | 2008-10-28 |
| EP1819710A1 (en) | 2007-08-22 |
| ATE425167T1 (de) | 2009-03-15 |
| US20090029955A1 (en) | 2009-01-29 |
| HK1101638A1 (en) | 2007-10-18 |
| EP1819710B1 (en) | 2009-03-11 |
| MX2007006173A (es) | 2007-07-09 |
| UY29239A1 (es) | 2006-02-24 |
| CN101068816A (zh) | 2007-11-07 |
| ZA200703827B (en) | 2008-08-27 |
| ES2259891A1 (es) | 2006-10-16 |
| DE602005013278D1 (de) | 2009-04-23 |
| AU2005311423A1 (en) | 2006-06-08 |
| IL183142A0 (en) | 2007-09-20 |
| PE20061078A1 (es) | 2006-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20073283L (no) | Nye pyridotienopyrimidinderivater | |
| NO20073271L (no) | Nye pyridotienopyrimidinderivater | |
| NO20092380L (no) | Amino-nikotin- og isonikotinsyrederivater anvendelige som DHODH-inhibitorer | |
| TW200800949A (en) | Macrocylic inhibitors of hepatitis C virus | |
| MX2010004819A (es) | Derivados de [1h-pirazolo[3,4-b]piridin-4-il]-fenilo o piridin-2-ilo como proteina cinasa c-theta. | |
| NO20084832L (no) | Pyrimidinderivater som P13K-inhibitorer | |
| MX2009006024A (es) | Derivados de heteroaril piridopirimidona sustituidos. | |
| NO20054952L (no) | 2,3,6-trisubstituerte 4-pyrimidonderivater | |
| NO20063446L (no) | Tiazolderivater | |
| NO20090952L (no) | N-(aminoheteroaryl) - lh - indol-2-karboksamidderivater og fremstilling og terapeutisk anvendelse derav | |
| TW200745118A (en) | Macrocylic inhibitors of hepatitis C virus | |
| NO20070173L (no) | Nye forbindelser | |
| NO20092770L (no) | Nye aminopyrimidinderivater som PLK1-inhibitorer | |
| NO20072115L (no) | Farmasoytiske forbindelser | |
| NO20072632L (no) | Oksadiazolderivater som DGAT-inhibitorer | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| ES2895626T3 (es) | Derivados de imidazol condensados como inhibidores de TGF-beta | |
| NO20073729L (no) | Heterocykliske forbindelser som CCR2B-antagonister | |
| NO20080871L (no) | N-(Heteroaryl)-1-heteroarylalkyl-1 H-indol-2-karboksamidderivater, fremstilling og terapeutisk anvendelse derav | |
| NO20073811L (no) | N-(heteroaryl)-1H-indol-2-karboksamidderivater og deres anvendelse som vanilloid TRPV1 reseptorligander | |
| NO20092689L (no) | Quinuclidinolderivater som muskarin reseptorantagonister | |
| NO20041531L (no) | Alkyleterderivater eller salter derav | |
| WO2009095792A3 (en) | Substituted heteroarylamide diazepinopyrimidone derivatives | |
| EA201170094A1 (ru) | Производные замещенного пиримидо[2,1-а]изохинолин-4-она | |
| MX2010008360A (es) | Derivados de oxazepinopirimidona heteroarilamida sustituidos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |